BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax is an oral BCL-2 inhibitor that received FDA approval for treating patients with relapsed CLL who had a 17p deletion.82 Subsequently, on the basis of the MURANO study (ClinicalTrials.gov identifier: NCT02005471), venetoclax with rituximab was approved for treating patients with CLL or small lymphocytic lymphoma who had received at least 1 previous therapy.